
DR 2313
CAS No. 284028-90-6
DR 2313( —— )
Catalog No. M24196 CAS No. 284028-90-6
DR 2313 is a competitive inhibitor of poly(ADP-ribose) polymerase (IC50: 0.20 and 0.24 μM for PARP-1 and PARP-2 respectively).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 45 | In Stock |
![]() ![]() |
10MG | 75 | In Stock |
![]() ![]() |
25MG | 149 | In Stock |
![]() ![]() |
50MG | 222 | In Stock |
![]() ![]() |
100MG | 330 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameDR 2313
-
NoteResearch use only, not for human use.
-
Brief DescriptionDR 2313 is a competitive inhibitor of poly(ADP-ribose) polymerase (IC50: 0.20 and 0.24 μM for PARP-1 and PARP-2 respectively).
-
DescriptionDR 2313 is a competitive inhibitor of poly(ADP-ribose) polymerase (IC50: 0.20 and 0.24 μM for PARP-1 and PARP-2 respectively). It also has neuroprotective.
-
In VitroDR2313 (0.016-16.4 μM; 30 min) inhibits poly(ADP-ribosyl)ation reaction in nuclear extracts of rat brain, with a Ki of 0.23 μM.DR2313 shows more powerful inhibition of the poly(ADP-ribosyl)ation in the nuclear extracts of the rat brain (IC50=0.20 μM) than 3AB (35.4 μM), PND (0.56 μM), DIQ (2.96 μM), and DPQ (0.96 μM).DR2313 (1-100 μM; 10 min) shows a weak inhibition of the mono(ADP-ribosyl)ation in a concentration-dependent manner (IC50=59 μM).DR2313 (0.1-30 μM; pretreated for 30 min) reduces hydrogen peroxide (500 μM; 4 h) or glutamate (1 mM; 30 min) induced excessive formation of poly(ADP-ribose) and cell death.
-
In VivoDR2313 (3-10 mg/kg i.v. bolus or infusion for 6 h) significantly reduces the cortical infarct volume in both permanent and transient focal ischemia models in rats. Animal Model:Male Wistar rats (220-300 g) with permanent MCA occlusions (pMCAos) and transient MCA occlusions (tMCAos)Dosage:3, 10 mg/kg Administration:I.v. bolus and i.v. infusion for 6 h beginning 5 min before the onset of ischemiaResult:Reduced the infarct volume in a dose-dependent manner in pMCAo and tMCAo model.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
RecptorPARP1|PARP2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number284028-90-6
-
Formula Weight182.24
-
Molecular FormulaC8H10N2OS
-
Purity>98% (HPLC)
-
SolubilityDMSO:83.3mg/mL;H2O:9.1mg/mL
-
SMILESO=C(N=C(C)N1)C2=C1CCSC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Nakajima H, et, al. A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. J Pharmacol Exp Ther. 2005 Feb;312(2):472-81.
molnova catalog



related products
-
SK-575
SK-575 is a degradation agent targeting protein-hydrolyzed PARP1 chimera with anticancer and antitumor activity.
-
Amelparib hydrochlor...
Amelparib hydrochloric hydrate (JPI-289, JPI289) is a novel potent, water soluble PARP-1 inhibitor with IC50 of 18.5 nM, inhibits cellular PAR formation with IC50 of 10.7 nM.
-
Amelparib
Amelparib (JPI-289, JPI289) is a novel potent, water soluble PARP-1 inhibitor with IC50 of 18.5 nM, inhibits cellular PAR formation with IC50 of 10.7 nM.